Tumor Profile Reports

About Tumor Profile Reports

Tumor profiles provide detailed information of a tumor’s molecularCancer Patients Struggle to Understand Clinical Trials characteristics.  That information can  point to therapies that may have the best chances for positive outcomes. These profiles are discovered by testing the tumor for biomarkers such homologous recombination deficiency (HRD), micro-satellite status (MS), and tumor mutation burden (TMB), as well as molecular changes in more than 300 genes.  You might ask your doctor if this testing has been ordered for you.

A tumor profile can be informative for women who are newly diagnosed and do not have an inherited BRCA gene mutation identified by a genetic test of their blood.  A BRCA mutation can sometimes be detected in the tumor but not the blood (called “somatic”) and this testing can determine if the tumor is positive. Patients who are BRCA positive in either of these tests may benefit from a PARP inhibitor as maintenance therapy after first line.

A positive HRD test result also suggests that a PARP inhibitor could be very effective.  HRD testing provides an estimate of the “BRCAness” characteristic of the tumor by measuring the genomic instability that results from problems with DNA damage repair.  This increased damage occurs in tumors that do not have a functional BRCA protein (e.g., due to a mutated BRCA gene) and also occurs when the BRCA gene is fine and the BRCA protein is not made by the cancer cell or when other genes in this repair pathway are mutated.  The tumor looks like BRCA is not working properly and the HRD test is positive.  Studies show that women whose tumors are HRD positive may receive more benefit from PARP inhibitor treatment in maintenance or recurrence than those whose tumors are HRD negative (also called HRP for homologous recombination proficient).

For women with recurrent or refractory ovarian cancer, a tumor profile can provide important new information to help guide their next treatment. In some cases, these genomic changes can suggest a clinical trial drug that is predicted to be effective to treat such tumors.

The Clearity Foundation can help patients understand the results from the tumor biomarker testing and comprehensive genomic analysis that is ordered by their physicians.  We generate our online-accessible interactive  report from those results.  This Tumor Profile Report provides information about the drugs that match and the reasons they match – all accessible by a mouse click.  This evidence comes from clinical research studies that have shown a correlation between genetic changes and drug effectiveness.  The report also provides links to clinical trials for drugs that are a match for the tumor biomarkers.  Active trials are regularly updated  to ensure timeliness of the information available.  The report is accessible through log in here.

In addition to the explanations provided in the Tumor Profile Reports, patients have access to Clearity’s staff, who have expertise in ovarian cancer molecular and cellular biology. These important consults help them understand their results and the unique nature of their cancer, as well as potential treatments and clinical trial options.

Clearity does not provide medical advice about which treatments they should receive. Instead, our staff explain tumor profile results and provide potential questions, and other information, which patients can discuss with their physicians.

How to Get Your Tumor Profile Report

It is likely that your physician has had your tumor tested to determine if there is a BRCA1 or BRCA2 mutation or for a biomarker called HRD (homologous recombination deficiency). The results from these tests can inform the choice of a PARP inhibitor for maintenance or for treatment of a recurrence.

For information about therapies other than PARP inhibitors, it can be useful to test your tumor with a more comprehensive genomic analysis that often includes more than 300 genes, as well as the BRCA1/2, HRD (or LOH, loss of heterozygosity), tumor mutation burden (TMB), and microsatellite instability (MSI).   Many laboratories perform this testing, including those in some of the large cancer centers and in companies such Foundation Medicine, Tempus, and Caris Life Sciences.  So, it is probable that your physician has already ordered this.

The results from such comprehensive testing can sometimes be hard to understand so Clearity’s scientific team summarizes the results from any laboratory in a report that is lay-friendly and interactive.  This report will indicate which treatments may prove helpful based on your tumor’s molecular profile. Some of those treatments may be available in clinical trials that are directly linked to the report.

To obtain your Tumor Profile Report, please complete our online background form to participate in our Treatment Decision Support Program.

Once completed, we will send you the appropriate consent and authorization forms.  

Please email Clearity at patientsupport@clearity.org  with any questions.

Reading Your Tumor Profile Report

This video shows a sample Tumor Profile report and offers tips on how to access the information and use it to make important decisions about your care.  Access to your report in our portal is privacy-protected and secure.